PCSA Insider Trading Activity and SEC Form 4 Filings
PCSA insider trading summary
Over the past 12 months, insiders at Processa Pharmaceuticals, Inc. (PCSA) reported 34 open-market purchases worth $170K by 9 insiders and no sales on SEC Form 4. Net insider buying was $170K.
Latest PCSA insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Jul 1, 2026 | George K Ng | Chief Executive Officer | Buy | $6K (3,057 @ $1.93) |
| Jun 30, 2026 | Patrick Lin | Chief Business - Strategy Off | Buy | $4K (2,106 @ $1.93) |
| Jun 30, 2026 | David Young | Pres. Research & Development | Buy | $5K (2,531 @ $1.93) |
| Jun 30, 2026 | Russell Skibsted | Chief Financial Officer | Buy | $6K (3,277 @ $1.93) |
| Jun 30, 2026 | Wendy Guy | Chief Administrative Officer | Buy | $5K (2,436 @ $1.93) |
| Jun 15, 2026 | George K Ng | Chief Executive Officer | Buy | $5K (2,465 @ $2.22) |
| Jun 15, 2026 | Patrick Lin | Chief Business - Strategy Off | Buy | $4K (1,831 @ $2.22) |
| Jun 15, 2026 | Russell Skibsted | Chief Financial Officer | Buy | $6K (2,654 @ $2.22) |
| Jun 15, 2026 | David Young | Pres. Research & Development | Buy | $5K (2,067 @ $2.22) |
| Jun 15, 2026 | Wendy Guy | Chief Administrative Officer | Buy | $5K (2,118 @ $2.22) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.